US healthcare giant Johnson & Johnson (NYSE: JNJ) announced the completion of a landmark agreement between its subsidiary Janssen Pharmaceuticals and South Africa’s largest drugmaker Aspen Pharmacare (JSE: APN) to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.
Aspen’s shares were up more than 4% at 18,259 rands following the announcement.
Expanding global vaccination coverage is critically important to controlling the COVID-19 pandemic and reducing the risk of emergence of new SARS-CoV-2 variants. Currently, only about 12% of people in Africa are fully vaccinated, which is well below the World Health Organization's target of 70% population coverage for all countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze